Normal view MARC view ISBD view

LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors.

Sabatel-Pérez, F

LDL cholesterol-lowering therapies: emphasis on proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. [electronic resource] - Drugs of today (Barcelona, Spain : 1998) May 2019 - 329-344 p. digital

Publication Type: Journal Article; Review

ISSN: 1699-3993

Standard No.: 10.1358/dot.2019.55.5.2976501 doi

Subjects--Topical Terms:
Anticholesteremic Agents--therapeutic use
Atherosclerosis--drug therapy
Cardiovascular Diseases--drug therapy
Cholesterol, LDL--antagonists & inhibitors
Humans
PCSK9 Inhibitors
Subtilisins--antagonists & inhibitors

Print
Cite
Add to your cart (remove)
Save record
BIBTEX Dublin Core MARCXML MARC (non-Unicode/MARC-8) MARC (Unicode/UTF-8) MARC (Unicode/UTF-8, Standard) MODS (XML) RIS ISBD
More searches

Search for this title in:
Other Libraries (WorldCat) Other Databases (Google Scholar) Online Stores (Bookfinder.com) Open Library (openlibrary.org)